Recombinant Anti-IL-6 antibody [EPR22565-204] (ab233551)


  • Product name

    Anti-IL-6 antibody [EPR22565-204]
    See all IL-6 primary antibodies
  • Description

    Rabbit monoclonal [EPR22565-204] to IL-6
  • Host species

  • Tested applications

    Suitable for: WB, Flow Cyt, IP, ICC/IFmore details
    Unsuitable for: IHC-P
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human IL-6 aa 1 to the C-terminus. The exact sequence is proprietary. HEK-293 expression system.
    Database link: P05231

  • Positive control

    • WB: HUVEC treated with LPS then BFA (Brefeldin A) whole cell lysate. ICC/IF: HUVEC treated with LPS then BFA (Brefeldin A) cells. Flow Cyt: HUVEC treated with LPS then BFA (Brefeldin A) cells. IP: HUVEC treated with LPS then BFA (Brefeldin A) whole cell lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab233551 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 21, 28 kDa (predicted molecular weight: 24 kDa).
Flow Cyt 1/400.
IP 1/20.
ICC/IF 1/100.
  • Application notes
    Is unsuitable for IHC-P.
  • Target

    • Function

      Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
    • Involvement in disease

      Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
      Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
    • Sequence similarities

      Belongs to the IL-6 superfamily.
    • Post-translational

      N- and O-glycosylated.
    • Cellular localization

    • Information by UniProt
    • Database links

    • Alternative names

      • Interleukin BSF 2 antibody
      • B cell differentiation factor antibody
      • B cell stimulatory factor 2 antibody
      • B-cell stimulatory factor 2 antibody
      • BSF 2 antibody
      • BSF-2 antibody
      • BSF2 antibody
      • CDF antibody
      • CTL differentiation factor antibody
      • Cytotoxic T cell differentiation factor antibody
      • Hepatocyte stimulating factor antibody
      • Hepatocyte stimulatory factor antibody
      • HGF antibody
      • HSF antibody
      • Hybridoma growth factor antibody
      • Hybridoma growth factor Interferon beta-2 antibody
      • Hybridoma plasmacytoma growth factor antibody
      • IFN-beta-2 antibody
      • IFNB2 antibody
      • IL 6 antibody
      • IL-6 antibody
      • IL6 antibody
      • IL6_HUMAN antibody
      • Interferon beta 2 antibody
      • Interferon beta-2 antibody
      • Interleukin 6 antibody
      • Interleukin 6 (interferon beta 2) antibody
      • Interleukin BSF 2 antibody
      • Interleukin-6 antibody
      see all


    • All lanes : Anti-IL-6 antibody [EPR22565-204] (ab233551) at 1/1000 dilution

      Lane 1 : Untreated HUVEC (human umbilical vein endothelial cell) whole cell lysate
      Lane 2 : HUVEC treated with 0.5 µg/ml LPS for 4 hours, then 300 ng/ml BFA (Brefeldin A) was added for the last 20 hours, whole cell lysate

      Lysates/proteins at 20 µg per lane.

      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Predicted band size: 24 kDa
      Observed band size: 21,24 kDa
      why is the actual band size different from the predicted?

      The molecular weight observed is consistent with what has been described in the literature (PMID: 14970177).

      Blocking/Dilution buffer: 5% NFDM/TBST.

    • Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HUVEC (human umbilical vein endothelial cell) cells labeling IL-6 with ab233551 at 1/100 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining in HUVEC cells treated with lipopolysaccharide (0.5µg/ml) for 4 h, then together with Brefeldin A (300ng/ml) for another 20h. The nuclear counterstain is DAPI (blue). Counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at a 1/200 dilution (red). The negative control is the secondary antibody only.

    • Flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol permeabilized HUVEC (Human umbilical vein endothelial cell) treated with 0.5ug/ml LPS for 4h, then together with 300ng/ml BFA for another 20h (Red) / Untreated control (Green), labeling IL-6 with ab233551 at 1/400 (red) compared with a Rabbit monoclonal IgG (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077), at 1/2000 dilution was used as the secondary antibody.

    • IL-6 was immunoprecipitated from 0.35 mg HUVEC (Human umbilical vein endothelial cell) treated with 0.5µg/ml LPS for 4h, then together with 300ng/ml BFA for another 20h whole cell lysate with ab233551 at 1/20 dilution. Western blot was performed from the immunoprecipitate using ab233551 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used at 1/5000 dilution.

      Lane 1: HUVEC treated as above whole cell lysate 10 µg (Input).

      Lane 2: ab233551 IP in HUVEC treated as above whole cell lysate.

      Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab233551 in HUVEC treated as above whole cell lysate.

      Blocking/Dilution buffer: 5% NFDM/TBST.
      Exposure time: 15 seconds.


    ab233551 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab233551.
    Please use the links above to contact us or submit feedback about this product.

    For licensing inquiries, please contact

    Sign up